NovAliX Collaborates with Bruker to Innovate Drug Discovery

Thursday, 8 August 2024, 12:49

French preclinical contract research organization (CRO) NovAliX has announced a strategic partnership with Bruker Corporation, a renowned manufacturer based in Massachusetts. This collaboration aims to leverage advanced technologies to improve drug discovery methods. With Bruker's minority investment, NovAliX looks to enhance its capabilities in the preclinical stage of drug development, ultimately benefiting the pharmaceutical industry and accelerating the timeline for new drug releases.
LivaRava Technology Default
NovAliX Collaborates with Bruker to Innovate Drug Discovery

Introduction

French preclinical CRO NovAliX has found a new partner across the pond.

Strategic Investment

Massachusetts-based manufacturer Bruker Corporation has announced a minority investment in the CRO.

Benefits of Collaboration

  • Advancing drug discovery techniques
  • Leveraging Bruker's technologies
  • Enhancing capabilities in preclinical stages

Conclusion

This partnership is set to transform the landscape of drug development, allowing NovAliX to strengthen its position in the industry and hasten the delivery of innovations.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most reliable and up-to-date tech news. Stay informed and elevate your tech expertise effortlessly.

Subscribe